Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 349

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 349
---
 DiamiR is not aware of any companies offering commercial miRNA -basedtests for brain health at this time. Advantages of DiamiR’s Technology Key advantages of DiamiR’s technology include the following: •DiamiR’s novel proprietary approach allows detecting molecular signatures of brain health in blood; •Liquid biopsy, blood -based, tests are minimally invasive, are potentially less expensive than current tests that rely on neuroimaging technologies and analysis of biomarkers in cerebrospinal fluid, and are therefore suitable for primary screening; •The proof -of -conceptdata generated to date indicates DiamiR’s approach may allow detecting and differentiating pathologies with high degree of accuracy; and •DiamiR’s technology is complementary, and potentially synergistic, to other diagnostic platforms, such as imaging and/or blood protein biomarkers. DiamiR’s tests are currently not commercially available. If the tests are successfully developed and launched, DiamiR believes that it will compete primarily on the basis of: •Clinical validation of DiamiR’s biomarker panels using samples from large heterogeneous cohorts from both retrospective and prospective clinical studies, including demonstration of correlation of DiamiR’s biomarkers with currently used biomarkers of AD and of the ability of DiamiR’s tests to specifically identify AD, and differentiate it from other NDs; •DiamiR’s ability to identify MCI, and predict whether a patient is likely to progress to AD or other NDs; •DiamiR’s ability to monitor disease progression and response to treatment; •Ease of use of DiamiR’s tests: they are minimally invasive, based on analysis of plasma; •Potential cost advantage of DiamiR’s tests compared to imaging and analysis of cerebrospinal fluid biomarkers; •DiamiR’s collaborations with high profile academic clinical centers; and •Value to customers (e.g. asymptomatic subjects in high -riskgroups) promoting repeat testing (e.g. annual screening). DiamiR believes that its success will depend on its ability to expeditiously: •Launch the tests in the US and expand in countries outside of the US; •Continue to innovate and maintain scientifically advanced technology; •Market and sell DiamiR’s tests, initially as a clinical research tool for pre -selectionof patients for AD trials; •Expand DiamiR’s tests to provide information on other NDs; •Optimize DiamiR’s sample collection process; 211 •Publish clinical studies in peer -reviewedjournals; •Continue to